Cyclin E and survival in patients with breast cancer.
By K. Keyomarsi, S. Tucker, T. Buchholz, M. Callister, Ye Ding, G. Hortobagyi, I. Bedrosian, C. Knickerbocker, W. Toyofuku, Michael Lowe and 2 more. New England Journal of Medicine, 2002
596 citations recorded by the source corpus.
Subfields: Oncology, Psychiatry and Mental health, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/8124354d78159e44d6452fe798eb75d17c33e8bb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. (2007, methodology): “both the LMW fragments of cyclin E and the intact molecule are considered together.(201) In a single-institution, retrospective study us-”
- Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. (2003, background): “New insight into prognosis and prediction of response has come from the extensive work on the urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 system,(2,3) and recently introduced technologies including gene profiling(4-7) and cyclin E determination.(8,9) However, the ”